We are live on ! Find out more
AVEO

AVEO Pharmaceuticals, Inc.
AVEO

Delisted

AVEO was delisted on the 19th of January, 2023.

Back to rankings

77 hedge funds and large institutions have $135M invested in AVEO Pharmaceuticals, Inc. in 2022 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 17 increasing their positions, 17 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,171% more call options, than puts

Call options by funds: $3.7M | Put options by funds: $291K

350% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 6

38% more funds holding

Funds holding: 56 → 77 (+21)

33% more capital invested

Capital invested by funds: $101M → $135M (+$33.8M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 17

Holders
77
Holders Change
+21
Holders Change %
+37.5%
% of All Funds
1.33%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
27
Increased
17
Reduced
17
Closed
6
Calls
$3.7M
Puts
$291K
Net Calls
+$3.41M
Net Calls Change
+$641K

Top Buyers

Rank Fund Capital Flow
1
RCMNY
Rubric Capital Management (New York)
New York
+$5.69M
2
GC
Globeflex Capital
California
+$2.83M
3
EGI
EAM Global Investors
California
+$1.63M
4
EI
EAM Investors
California
+$1.49M
5
Invesco
Invesco
Georgia
+$1.32M

Top Sellers

Rank Fund Capital Flow
1
JGC
J. Goldman & Co
New York
-$5.09M
2
Millennium Management
Millennium Management
New York
-$3.78M
3
ACM
AIGH Capital Management
Maryland
-$1.6M
4
SSA
Schonfeld Strategic Advisors
New York
-$1.54M
5
WVP
Worth Venture Partners
New Jersey
-$241K
Name Holding Trade Value Shares
Change 		Change in
Stake
VIA
51
Virtus Investment Advisers
Connecticut
$104K +$97.3K +12,674 New
DWM
52
Dakota Wealth Management
Florida
$103K – – –
CPC
53
Cookson Peirce & Co
Pennsylvania
$99K +$92.2K +12,000 New
Charles Schwab
54
Charles Schwab
California
$92K -$46.1K -6,002 -35%
PCS
55
Personal CFO Solutions
New Jersey
$82K – – –
Barclays
56
Barclays
United Kingdom
$65K +$15.7K +2,044 +35%
Lazard Asset Management
57
Lazard Asset Management
New York
$62K – – –
BNP Paribas Financial Markets
58
BNP Paribas Financial Markets
France
$49.3K +$46K +5,985 New
Citigroup
59
Citigroup
New York
$40K -$3.07K -400 -8%
TRCT
60
Tower Research Capital (TRC)
New York
$23K +$16.2K +2,106 +333%
QT
61
Quantbot Technologies
New York
$22K +$21.3K +2,777 New
UBS Group
62
UBS Group
Switzerland
$13K -$3.86K -502 -23%
Osaic Holdings
63
Osaic Holdings
Arizona
$13K +$545 +71 +5%
CWM
64
CarsonAllaria Wealth Management
Illinois
$12K – – –
Royal Bank of Canada
65
Royal Bank of Canada
Ontario, Canada
$10K +$2.53K +329 +41%
Simplex Trading
66
Simplex Trading
Illinois
$10K +$9.82K +1,279 New
MCM
67
Magnolia Capital Management
New York
$8K – – –
Federated Hermes
68
Federated Hermes
Pennsylvania
$5K +$4.87K +634 New
WIM
69
Westside Investment Management
California
$4.12K – – –
PHK
70
Point72 Hong Kong
Hong Kong
$4K +$3.59K +467 New
Wells Fargo
71
Wells Fargo
California
$2K -$2.14K -279 -60%
TFGT
72
TS Financial Group (TSFG)
Illinois
$2K – – –
S
73
SignatureFD
Georgia
$2K +$2.3K +300 New
AF
74
Advisornet Financial
Minnesota
$1K – – –
JP Morgan Chase
75
JP Morgan Chase
New York
$1K +$38 +5 +5%
1 2
3
4

AVEO Hedge Fund Activity: Q3 2022 in Review

77 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q3 2022, worth a combined $135M — up 33% from $101M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new AVEO positions and 6 closed out — a net gain of 21 holders — while 17 added to existing stakes and 17 trimmed.

The largest buyer was Rubric Capital Management (New York), adding an estimated $5.69M. The largest seller was J. Goldman & Co, cutting an estimated $5.09M.

  • 77 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q3 2022, up from 56 in Q2 2022.
  • Funds reported $135M of AVEO Pharmaceuticals, Inc. stock for Q3 2022, up 33% quarter-over-quarter.
  • 27 funds opened new AVEO Pharmaceuticals, Inc. positions in Q3 2022 and 6 closed out, a net change of +21 holders.
  • The largest AVEO Pharmaceuticals, Inc. buyer in Q3 2022 was Rubric Capital Management (New York), an estimated $5.69M added.
  • The largest AVEO Pharmaceuticals, Inc. seller in Q3 2022 was J. Goldman & Co, an estimated $5.09M sold.

Based on aggregated 13F filings for Q3 2022.